India's Quest for Pharma Self-Sufficiency: Reducing Dependence on China

India, known as the "pharmacy of the world," had embarked on an ambitious plan in 2022 to reduce its dependence on China for key raw materials in the pharmaceutical sector. While India is already the third-largest manufacturer of medicines by volume and boasts low manufacturing costs, it heavily relies on China for active pharmaceutical ingredients (APIs) – chemicals crucial for the therapeutic effect of drugs. Estimates suggest that India's dependence on China for certain drugs may be as high as 90%.

Realizing the need to become self-sufficient and enhance its pharmaceutical sector, India has implemented strategies to address this dependence. One such initiative is a government scheme launched three years ago, aiming to produce 35 APIs at 32 plants across the country by March. This move is expected to reduce India's reliance on China by up to 35% before the end of the decade, according to ICRA Limited, an Indian affiliate of Moody's.

The production linked incentive (PLI) scheme, launched in 2020 amid military tensions with China, incentivizes companies in all sectors to boost domestic manufacturing. Within the pharma sector, the government has allocated over $2 billion worth of incentives for both Indian and foreign companies to produce 53 APIs that India heavily imports from China.

The first phase of the scheme has already seen the approval of 34 products, distributed among 49 players. Deepak Jotwani, Assistant Vice President at ICRA Limited, estimates that this phase alone will reduce India's imports from China by about 25-35% by 2029. These efforts are part of a broader goal to elevate the pharmaceutical sector's value from $42 billion to $65 billion by 2024 and eventually reach $120 billion to $130 billion by 2030.

India's significance in the global fight against the pandemic should not be overlooked. The country has played a crucial role in supplying vaccines worldwide, providing over 201 million doses to approximately 100 countries across various regions. Through government-funded initiatives and the Covax platform, India has been instrumental in vaccine distribution. Additionally, Indian pharmaceutical firms supply more than 80% of the antiretroviral drugs used globally to combat AIDS.

It is important to note that India was not always heavily dependent on China for essential drug ingredients. However, with the implementation of strategic initiatives and incentives, India aims to reduce this dependence and strengthen its position as a self-sufficient pharmaceutical powerhouse.

As India continues on its path to pharmaceutical self-sufficiency, the global healthcare landscape can expect a more diversified supply chain, reduced vulnerabilities, and increased stability in the production of essential drugs. This progress aligns with India's vision to become a global leader in pharmaceuticals while ensuring access to affordable and high-quality medicines for its population and the world.